Understanding the Therapeutic Potential of Interleukin-1 Inhibition in Intracerebral Haemorrhage.

Project Details


Inflammation worsens brain damage after bleeding into the brain. Interleukin-1 is a messenger molecule driving this damage. IL1-Ra is a licenced drug that blocks interleukin-1 and may improve recovery from brain haemorrhage. We will measure interleukin-1 levels in the brain after haemorrhage using samples from an ongoing surgical clinical trial. We will test how easily IL-1Ra might enter the brain after brain haemorrhage using advanced scans. These first two studies will help decide the best dose of IL-1Ra and how long we need to give it for. We will then test whether IL-1Ra reduces brain swelling in intracerebral haemorrhage patients.
Short titleR:KBA Interleukin-1
Effective start/end date1/03/1529/02/20

Collaborative partners

  • The University of Manchester (lead)
  • Royal Free London NHS Foundation Trust (Collaborator)
  • Ideagen Gael Ltd (Collaborator)
  • Swedish Orphan Biovitrum AB (Collaborator)
  • NHS Grampian (Collaborator)
  • NHS Greater Glasgow & Clyde (Collaborator)
  • St George's University Hospitals NHS Foundation Trust (Collaborator)
  • University College London Hospitals NHS Foundation Trust (Collaborator)

UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.